Table 1.

Population data of both treatment groups.

	Aranesp group	Eprex group	Total	P-value
Study population, n (%)	67 (52.8%)	60 (47.2%)	127	—
Gender, n (%)
Male	47 (70.1%)	36 (60.0%)	83 (65.4%)	0.230*
Female	20 (29.9%)	24 (40.0%)	44 (34.6%)
Age (years) (mean ± SD)	59.5 ± 10.2	62.4 ± 8.5	60.9 ± 9.5	0.099**
Weight (kg) (mean ± SD)	84.4 ± 11.5	84.7 ± 13.8		0.927**
Smoking status, n (%)
Smoker(s)	9 (13.4%)	4 (6.7%)	13 (10.2%)	0.209*
Etiology, n (%)
Hypertension	27 (40.3%)	30 (50%)	57 (44.9%)	0.655*
Diabetes	10 (14.9%)	9 (15%)	19 (15%)
Hypertension and diabetes	20 (29.9%)	11 (18.3%)	31(24.4%)
SLE	4 (6.0%)	4 (6.7%)	10 (7.9%)
Unknown	6 (9.0%)	6 (10%)	10 (7.9%)
Hepatitis status, n (%)
HCV +ve	20 (29.9%)	18 (30%)	38 (29.9%)	0.985*
Vascular access, n (%)
AVF	15 (82.1%)	54 (90.0%)	109 (85.8%)	0.202*
Permcath catheter	12 (17.9%)	6 (10%)	18 (14.2%)

SLE, systemic lupus erythematosus; HCV, hepatitis C virus; AVF, arteriovenous fistula.

^*P-values were obtained by a chi-square test.

^**P-values were obtained by the Mann-Whitney U test.